California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
NCT06716554
Recruiting
This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of Shatavari for the treatment of Menopausal symptoms in Women. Participants will be randomized to either one of the three treatment arms.Participants will then be asked to either take one capsule containing Shatavari or Shatavari + Ashwagandha or Placebo orally once daily in the morning after breakfast with a glass of water for 8 weeks. All the s... Read More
Gender:
FEMALE
Ages:
Between 45 years and 55 years
Trial Updated:
11/29/2024
Locations: SF Research Institute, Inc., San Francisco, California
Conditions: Menopause, Hot Flashes, Mood
Register for Updates
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT06708429
Recruiting
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM. Despite ad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Beckman Research Institute at City of Hope, Monrovia, California
Conditions: Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, Lynch Syndrome I (Site-specific Colonic Cancer), HNPCC, HNPCC Gene Mutation, Hereditary Cancer Syndrome, Hereditary Cancer, MLH1 Gene Mutation, MLH1 Gene Deletion+Duplication, MLH1 Loss of Expression, MLH1 Gene Inactivation, MSH2 Gene Mutation, MSH2 Gene Deletion+Duplication, MSH2 Loss of Expression, MSH2 Gene Inactivation, MSH6 Gene Mutation, MSH6 Loss of Expression, MSH6 Gene Inactivation, PMS2 Gene Mutation, PMS2 Gene Inactivation, PMS2 Loss of Expression
Register for Updates
STXBP1 and SYNGAP1 Related Disorders Natural History Study
NCT06555965
Recruiting
The purpose of this study is to find out more about STXBP1 and SYNGAP1 related disorders. The information gathered by this study will be used to prepare for clinical treatment trials. The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care.
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2024
Locations: Stanford Medicine Children's Health, Palo Alto, California
Conditions: Genetic Disease, STXBP1 Encephalopathy With Epilepsy, SYNGAP1-Related Intellectual Disability
Register for Updates
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
NCT06440850
Recruiting
This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form of a gene called BRAF. They are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Register for Updates
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
NCT06094205
Recruiting
The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/27/2024
Locations: University of California, Davis, Sacramento, California
Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophies
Register for Updates
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
NCT05724173
Recruiting
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/27/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Register for Updates
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
NCT05438732
Recruiting
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/27/2024
Locations: Loma Linda University, Loma Linda, California
Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Register for Updates
Addressing Diabetes by Elevating Access to Nutrition
NCT05228860
Recruiting
The goal of ADELANTE is to determine whether a multi-level intervention to improve household food insecurity and glycemic control is effective for Latino patients with diabetes. Specifically, ADELANTE aims to 1. determine whether weekly household food delivery plus an intensive lifestyle intervention is more effective than usual care for improving glycemic control (HbA1c) at 6 months, 2. examine the effects of the multi-level intervention on = household food insecurity, dietary behaviors, and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: La Clínica Monument, Concord, California
Conditions: Diabetes, Obesity, Lifestyle, Healthy
Register for Updates
The GAstric Precancerous Conditions Study
NCT04191551
Recruiting
Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) are precancerous changes to the stomach mucosa which increases risk for subsequent gastric cancer. The Gastric Precancerous Conditions Study (GAPS) is an ob... Read More
Gender:
ALL
Ages:
Between 35 years and 84 years
Trial Updated:
11/27/2024
Locations: Stanford University, Stanford, California
Conditions: Gastric Cancer, Intestinal Metaplasia of Gastric Mucosa, Helicobacter Pylori Infection, Atrophic Gastritis
Register for Updates
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT01019148
Recruiting
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Epidermolysis Bullosa Dystrophica
Register for Updates
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
NCT06706921
Recruiting
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT (18F-DCFPyL (2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California
Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
Register for Updates
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
NCT06424834
Recruiting
The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Stanford Hospital, Palo Alto, California
Conditions: Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Register for Updates